Key result
Magnesium sulfate cuts postoperative AF by ~100% versus dexmedetomidine in off-pump CABG.
Why the study?
Atrial fibrillation often occurs after heart surgery and causes serious complications, but the comparative efficacy of dexmedetomidine versus magnesium sulfate in preventing it after off-pump CABG was unclear.
Does dexmedetomidine compared to magnesium sulfate reduce the incidence of postoperative atrial fibrillation in patients undergoing off-pump CABG?
RCT (n=20)
Randomized
No
Does dexmedetomidine compared to magnesium sulfate reduce the incidence of postoperative atrial fibrillation in patients undergoing off-pump CABG?
Absolute Event Rate: 50% vs 0%
p-value: p=0.032
Magnesium sulfate is more effective than dexmedetomidine in preventing postoperative atrial fibrillation and is associated with fewer hemodynamic adverse events like hypotension and bradycardia in patients undergoing off-pump CABG.
Supports preferring magnesium sulfate over dexmedetomidine to prevent postoperative atrial fibrillation after off-pump CABG; extends RCT evidence for magnesium prophylaxis.
Introduction The main goal of this study is to compare the effects of dexmedetomidine and magnesium sulfate on preventing atrial fibrillation (AF) after off-pump coronary artery bypass graft (CABG) surgeries. AF is a type of irregular heartbeat that often occurs after heart surgery and can cause serious complications. We want to see which drug is more effective in reducing the risk of AF in patients who have had CABG surgeries without using a heart-lung machine. Materials and methods This was a randomized clinical study, conducted on patients of ASA classes III and IV who were the candidates for off-pump coronary artery bypass graft surgeries, which were conducted in the cardiac operating room from the period October 2020 to April 2021, at the Department of Anaesthesia, Jawaharlal Nehru Medical College, Sawangi, Meghe. All patients were aged between 30 and 85 years and with a left ventricular ejection fraction of above 40%. Results When the two groups were compared, the incidence of arrhythmias was more in group D (a group that received injection dexmedetomidine infusion), predominantly AF with an incidence of 50% more as compared to group M (a group that received injection magnesium sulfate infusion). When hemodynamic parameters were compared, events of bradycardia and hypotension were significantly higher in group D as compared to group M. The heart rate (HR), when compared between the two groups intraoperatively from the duration before induction of anesthesia till during sternum closure, has a significant p-value (0.0001). Similarly, when the mean arterial pressure (MAP) was compared between the two groups intraoperatively, significant hypotension was noted in group D (p-value = 0.0001). Postoperatively, in the intensive care unit when the HR and MAP were compared for 48 hours, bradycardia and hypotension were noted, but drastic changes in the mean values of the HR and MAP were not seen in both groups D and M. Conclusion When comparing the antiarrhythmic properties of the study drugs, it was observed that intraoperative and postoperative arrhythmias were less with magnesium sulfate as compared with dexmedetomidine. It was also found that there were higher events of hypotension and bradycardia in the dexmedetomidine group as compared to the magnesium sulfate group.
No takes yet. Share an insight, caveat, or question.
Jadhav et al. (2023) conducted an RCT in Off-pump coronary artery bypass graft (CABG) surgery (n=20). Dexmedetomidine vs. Magnesium sulfate (20 ug/kg/min infusion) was evaluated on Occurrence of atrial fibrillation (AF) (p=0.032). Magnesium sulfate reduced the incidence of postoperative atrial fibrillation to 0% compared to 50% with dexmedetomidine in patients undergoing off-pump coronary artery bypass graft surgeries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: